We have been following Glucoband since June 13th 2005 when it obtained positive pre-clinical results. Now, after almost a year, Calisto Medical Inc. will release its latest prototype of Glucoband in Washington D.C. at the 66th Scientific Session of the American Diabetes Association taking place June 10-13, 2006.
Calisto Medical Inc. (CMI), a Texas-based bio-medical technology company has successfully completed its first round of funding. CMI is pleased to announce that Dallas-based Scientific Health Development (SHD) has joined our founding investors, Dr. Vahram Mouradian and Mr. Zareh Baghdasarian.
Calisto Medical Inc. specializes in development and marketing of technology for portable non-invasive devices for medical telemetry, including measurement and continuous monitoring. In particular, CMI is currently focused on developing technologies and products based on the bio-resonance (BR) phenomena. A patent application is pending for approval in the USA, Europe and Asia.
The funding will support further research and development and the first industrial prototyping of Glucoband, CMI’s flagship product. Glucoband is the first truly non-invasive portable blood glucose monitor that measures, records and continuously monitors blood glucose levels in the human body.
Prototypes of Glucoband have been hand assembled for pre-clinical testing. An internal pre-clinical trial using several prototype versions of Glucoband has been conducted, in which measurements taken by Glucoband successfully corresponded to those of a conventional (commercial) invasive device.
The first commercial prototype units will be released and subsequently used in clinical tests in compliance with ISO 15197 in early 2007. Soon after, CMI expects to start pilot production of Glucoband for commercial distribution.
More at Calisto Medical Inc.